Research Article

SIRT1 Mediates Neuropathic Pain Induced by Sciatic Nerve Chronic Constrictive Injury in the VTA-NAc Pathway

Yangyang Li,1 Lei Wang,2 Guotao Zhang,3 Xueli Qiao,3 and Mingxing Zhang3

1Department of Anesthesiology, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University, Huai’an 223001, China
2Department of Anesthesiology, The Affiliated Huai’an Hospital of Xuzhou Medical University and the Second People’s Hospital of Huai’an, Huai’an 223001, China
3Department of Pharmacy, The Affiliated Huai’an Hospital of Xuzhou Medical University and the Second People’s Hospital of Huai’an, Huai’an 223001, China

Correspondence should be addressed to Mingxing Zhang; nongyuyayu@163.com

Received 12 March 2020; Revised 12 June 2020; Accepted 1 July 2020; Published 19 August 2020

Academic Editor: Shinya Kasai

Copyright © 2020 Yangyang Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Mounting evidence has shown that sirtuin 1 (SIRT1), a class III histone deacetylase, alleviated several types of neuropathic pain in the spinal cord and dorsal root ganglion and regulated some aberrant behaviors in the ventral tegmental area (VTA) and the nucleus accumbens (NAc). Methods. In this context, the effect of SIRT1 on neuropathic pain in the VTA-NAc pathway was investigated in the model of chronic constrictive injury (CCI). Results. SIRT1 was localized in the VTA neurons in naive mice. The expression of SIRT1 was decreased in the contralateral VTA of CCI mice. After microinjection of SRT1720 (an activator of SIRT1) in the contralateral VTA of CCI mice, the established thermal hyperalgesia was attenuated. However, it was further exacerbated by EX-527 (an inhibitor of SIRT1). The elevated level of acetyl-histone 3 was reduced by SRT1720 but further elevated by EX-527 in the contralateral VTA of CCI mice. The increased expression of Fos in both VTA and NAc was downregulated by SRT1720 but further upregulated by EX-527 in CCI mice. Conclusions. The discovery of the effect of SIRT1 on neuropathic pain in the VTA represents an important step forward in understanding the analgesic mechanisms of the VTA-NAc pathway.

1. Introduction

Chronic pain is a highly prevalent and intractable disease in the world, leading patients to wind up in a constant state of pain and contributing to high costs of health care and productivity loss [1–5]. Neuropathic pain, a kind of chronic pain, is defined by the International Association for the Study of Pain (IASP) as a pain arising after lesions or diseases, which affect the somatosensory system [6]. Epidemiological research studies show that the prevalence of neuropathic pain may be 7–8% in general population [7, 8], accounting for 20–25% of individuals with chronic pain [9]. Central sensitization, which augments responsiveness (amplification) of nociceptive neurons in the central nervous system to normal or subthreshold afferent inputs in the spinal cord and brain, may be a crucial mechanism and also a potential therapeutic target for neuropathic pain [10–13]. Mesolimbic reward circuitry, which is composed of dopaminergic (DA) neurons of the ventral tegmental area (VTA) and their projections to several brain regions, is pivotal for pain sensation [14–22]. Functional magnetic resonance images revealed that reward circuitry could be activated by noxious stimuli in healthy volunteers [23, 24]. The VTA, as a mesencephalic nucleus, is recently found to participate in pain sensation induced by mechanical stimulation, electrical foot shock, nerve injury, bone cancer, or formalin [15, 25–27]. The nucleus accumbens (NAc), a key projectional region of VTA DA neurons, plays an analgesic role in neuropathic pain [19, 20, 28–30].
Sirtuin 1 (SIRT1), a NAD⁺-dependent class III histone deacetylase, is deemed as a potential therapeutic target for several chronic diseases which are more common in elderly population, such as type 2 diabetes, cardiovascular diseases, cancers, age-related macular degeneration, and neurodegenerative diseases [31–35]. Additionally, SIRT1 has been reported to regulate anxiety, depressive and exploratory behaviors, and behaviors associated with drug abuse in the VTA and NAc [36–42]. Recent research studies illustrate that SIRT1 alleviates neuropathic pain induced by type 2 diabetes, Freund’s adjuvant, bortezomib, paclitaxel, or chronic constriction injury (CCI) in the spinal cord and dorsal root ganglion [43–48]. The analgesic mechanisms of SIRT1 in the spinal cord and dorsal root ganglion are based on the epigenetic regulation of mGluR1/5, postsynaptic density protein 95 (PSD-95), growth-associated protein 43 (GAP43), c-fos, mammalian target of rapamycin (mTOR), nuclear factor-κB (NF-κB), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and inducible nitric oxide synthase (iNOS) expression [43–49]. Furthermore, immunohistochemistry staining showed that the expression of the c-fos gene, a neural marker of pain, was upregulated in the VTA-NAc pathway induced by CCI [22]. Intrathecal injection of c-fos antisense oligodeoxynucleotide to block c-fos gene expression decreased the nociceptive behaviors induced by formalin and Freund’s adjuvant [50, 51].

Based on these findings, we reasoned that SIRT1 in the VTA-NAc pathway might mediate neuropathic pain through regulating Fos expression. Here, we showed that SIRT1 in the VTA-NAc pathway ameliorated neuropathic pain induced by sciatic nerve CCI.

2. Methods

2.1. Animals. The male mice, 18–22 g, were housed in a controlled condition (23 ± 2°C and 20%–30% humidity). The care and experimental procedures were performed in accordance with and approved by the Institutional Animal Care and Use Committee of Xuzhou Medical College. After 3 days of acclimatization, behavioral testing was performed to eliminate the mice exhibiting hyperalgesia or dysesthesia to pain. 12 days after the surgery, the CCI mice exhibiting hyperalgesia were microinjected with SRT1720, EX-527, or vehicle. 12h after the microinjection, the effect of SRT1720 and EX-527 on neuropathic pain was indicated by behavioral testing.

2.3. Behavioral Testing. Thermal nociception was assessed by measuring paw withdrawal latencies in response to thermal stimulation according to the protocol by Hargreaves et al. [53]. Mice were individually placed in chambers (7 × 9 × 11 cm) on an elevated glass platform and were allowed to acclimate to the environment for 1 h in a temperature-controlled (23 ± 2°C) and noise-free room. The high-intensity radiant lamp source placed underneath the glass plate (the thickness is about 3 mm) was focused onto the left plantar surface. The heat source was turned off when the paw withdrew. The interval time between the onset of radiant lamp application and the left paw withdrawal was recorded. The automatic cutoff time was 20 s to prevent tissue damages. The interval time of thermal stimulation was 5 min. The maximum and minimum of five values were deleted and the average of the remaining three values was deemed as the thermal withdrawal latency (TWL). 12 days after the surgery, the decrease in TWL in CCI mice indicated the success in the establishment of the neuropathic pain model.

2.4. Stereotaxic Surgery and Microinjection. Mice were anesthetized and positioned on the Stoelting Stereotaxic Instrument (David Kopf Instruments, Tujunga, CA). The drill coordinate for the Hamilton syringe needle was antero-posterior (AP) −3.5 mm, mediolateral (ML) ±0.5 mm, and dorsoventral (DV) −0.4 mm. 0.05 µg/0.5 µL SRT1720 (APEXBio, Houston, TX, USA) or 0.1 µg/0.5 µL EX-527 (APEXBio) was unilaterally infused at a rate of 0.1 µL/min with a microinfusion pump (Harvard Apparatus, Holliston, MA, USA). Mice in the sham and CCI groups were injected with 0.5 µL 1% dimethyl sulfoxide. An additional 5 min was allowed for diffusion and prevention of backflow.

2.5. Double Immunofluorescent Staining. The double immunofluorescent staining experiment was conducted on the brains of naive mice. Glial fibrillary acidic protein (GFAP), Iba-1, and NeuN are, respectively, regarded as the markers of the astrocyte, microglia, and neuron. After deeply anesthetized with pentobarbital sodium (40 mg/kg, i.p.), mice
were perfused transcardially with 0.1 M precooling phosphate-buffered saline (PBS), followed by 4% paraformaldehyde (dissolved in PBS). The brains were removed and postfixed in 4% paraformaldehyde at 4°C for 24 h and then allowed to equilibrate in 30% sucrose (dissolved in PBS) until sinking to the bottom. The brains were sectioned to 30 μm coronal sections by a cryostat (Leica, Wetzlar, Germany) at −20°C and stored in a frozen stock solution at −20°C. After being washed by PBS, the brain sections were blocked with the blocking buffer (3% goat serum and 1% Triton X-100) for 2 h. Thereafter, the sections were incubated with the anti-SIRT1 antibody (1:100; Abcam, Cambridge, UK) plus anti-GFAP antibody (1:100; Cell Signaling Technology Inc., Beverly, MA, USA), anti-Iba-1 antibody (1:100; Abcam), or anti-NeuN antibody (1:100; Cell Signaling Technology Inc.) respectively, for 48 h at 4°C. After being washed with PBS, the sections were incubated with the suitable secondary antibodies: Alexa Fluor® 594 Donkey anti-mouse IgG (Life Technologies, Shanghai, China) and Alexa Fluor® 488 Donkey anti-Rabbit IgG (Life Technologies) in the darkness for 2 h. Thereafter, the sections were stained with 4',6-diamidino-2-phenylindole (DAPI). Cellular colocalization was observed under a fluorescence microscope (Olympus, Tokyo, Japan).

2.6. Western Blotting Analysis. The tissues were homogenized in the lysis buffer containing a cocktail of protease inhibitors and phenylmethylsulfonyl fluoride (KeyGEN BioTECH, Jiangsu, China). After centrifugation at 12000 g for 15 minutes at 4°C, the supernatant was used for western blotting analysis. The protein concentration was measured with a BCA Protein Assay Kit (KeyGEN BioTECH). An equal amount of protein samples was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blot analysis was applied to analyze the combination between SIRT1 and its subunit acetyl-histone 3 by incubating the blots with these two primary antibodies at the same time.

2.8. Statistical Analysis. All data were presented as mean ± standard deviation (SD). Statistical analyses were conducted by one-way ANOVA followed by LSD (if the variance is equal) or the Dunnett T3 test (if the variance is not equal). Results were considered to be significantly different when P < 0.05.

3. Results

3.1. SIRT1 Localizes in the VTA Neuron but Not Astrocyte or Microglia. The double immunofluorescent staining experiment was firstly conducted to investigate the location of SIRT1 in the VTA. GFAP, Iba-1, and NeuN are regarded as the markers of the astrocyte, microglia, and neuron, respectively. The results showed that SIRT1 (red) was almost colocalized with NeuN (green) in the VTA. However, overlaps of SIRT1 (red) with GFAP (green) or Iba-1 (green) were rarely seen (Figure 2). These results indicate that SIRT1 may be involved in regulating neuronal function in the VTA.

3.2. Upregulation of SIRT1 Attenuates Pain Behavior and VTA Neuronal Activation in CCI Mice. To investigate the role of SIRT1 in neuropathic pain, SRT1720, a selective SIRT1 agonist, was microinjected into the contralateral VTA. 12 h later, a behavioral test was performed. CCI mice exhibited thermal hyperalgesia in the affected hind paws, which was mitigated by SRT1720 (Figure 3(a)). Contrary to the changes of pain behavior, the downregulated expression of SIRT1 in the contralateral VTA of CCI mice was upregulated by SRT1720 (Figure 3(b)). Furthermore, the modifications of histone 3 are involved in the epigenetic modulations of gene expression. The acetylation of histone 3, regulated by the histone deacetylases and histone acetyltransferases, is involved in the initiation and maintenance of pain [44, 54]. Coimmunoprecipitation analysis revealed that the level of acetyl-histone 3, a substrate of SIRT1, was elevated in the contralateral VTA of CCI mice, and the degree of elevation was decreased by SRT1720 (Figure 3(c)). It is known that the Fos protein, the product of the c-fos immediate early gene, has been deemed as a marker for neuronal activation in the central nervous system [55–57]. Western blotting analysis revealed that SRT1720 alleviated the increased expression of Fos in the contralateral VTA of CCI mice (Figure 3(d)). These results indicate that upregulating the expression of SIRT1 by SRT1720 may ameliorate hyperalgesia and inhibit the VTA neuronal activation induced by CCI.

3.3. Downregulation of SIRT1 Aggravates Pain Behavior and VTA Neuronal Activation in CCI Mice. To validate the effect of SIRT1 on neuropathic pain in the VTA, EX-527, a
selective SIRT1 inhibitor, was employed in this study. EX-527 significantly decreased the TWL in sham-operated mice and further decreased the TWL in CCI mice (Figure 4(a)). EX-527 significantly inhibited the expression of SIRT1 in the contralateral VTA in sham-operated and CCI mice (Figure 4(b)). Moreover, the coimmunoprecipitation experiment indicated that EX-527 significantly increased the level of acetyl-histone 3 in the contralateral VTA of sham-operated and CCI mice (Figure 4(c)). In addition, western blotting analysis revealed that EX-527 significantly upregulated the expression of Fos in the contralateral VTA of sham-operated and CCI mice (Figure 4(d)). These results indicate that downregulating the expression of SIRT1 by EX-527 may exacerbate hyperalgesia and activate the VTA neurons in sham-operated and CCI mice.

3.4. SIRT1 in the VTA Inhibits the NAc Neuronal Activation in CCI Mice. The NAc is a key projectional region of VTA neurons, playing an analgesic role in neuropathic pain. To further probe the analgesic mechanism of SIRT1 in the VTA, western blotting analysis was conducted. SRT1720 microinjected in the VTA alleviated the increased level of Fos in the contralateral NAc neurons induced by CCI (Figure 5(a)); nevertheless, EX-527 significantly aggravated the expression of Fos (Figure 5(b)). These results demonstrate that SIRT1 in the VTA mediates neuropathic pain, maybe through inhibiting the activation of neurons in the NAc, which is the projectional region of VTA DA neurons.

4. Discussion

Central sensitization has been identified as a crucial mechanism for regulating hyperalgesia and also a potential therapeutic target for neuropathic pain, through augmenting responsiveness of nociceptive neurons in the central nervous system to normal or subthreshold afferent inputs in the spinal cord and the brain. Mounting evidence reveals that mesolimbic reward circuitry, which is composed of DA neurons of VTA and their projections to NAc, is pivotal for pain sensation [14–22]. As an NAD⁺-dependent histone deacetylase, SIRT1 is extensively studied in several senile diseases including type 2 diabetes, cardiovascular diseases, cancers, age-related macular degeneration, and neurodegenerative diseases. Moreover, SIRT1 has been implicated in regulating anxiety, depressive and exploratory behaviors, and the behaviors associated with drug abuse in the VTA and NAc [36–42]. Recently, research studies illustrate the analgesic effect of SIRT1 on neuropathic pain induced by Freund’s adjuvant, bortezomib, chronic constriction injury, and paclitaxel in the spinal cord and the dorsal root ganglion [43, 45–48]. Our previous research has shown that SIRT1-mediated epigenetic regulation of mGluR1/5 expressions were involved in the development of neuropathic pain in type 2 diabetic rats [44]. The objective of the present study was to explore the possible role of SIRT1 in neuropathic pain induced by CCI in the VTA-NAc pathway.

In this study, we firstly conducted a double immunofluorescent staining experiment to investigate the location of SIRT1 in the VTA. The results showed that SIRT1 almost colocalized with NeuN, indicating that SIRT1 might regulate neuronal functions in the VTA. In the following experiments, we found that the expression of SIRT1 was inhibited in the contralateral VTA of sham-operated and CCI animals. Moreover, established thermal hyperalgesia was attenuated by SRT1720 but further exacerbated by EX-527, indicating that SIRT1 in the VTA may participate in analgesia. Recent research studies have substantiated that acetyl-histone 3 might be a key analgesic target for SIRT1 in neuropathic pain induced by CCI and type 2 diabetes [44, 54]. Our data suggested that acetyl-histone 3 in the VTA was involved in the analgesic effect of SIRT1 in CCI models. The Fos protein has been considered as the marker and causal contributor for neuronal activation in the central nervous system [50, 51, 54–56]. We found that the elevated level of the Fos protein in both VTA and NAc was decreased by SRT1720 but further increased by EX-527 in CCI mice, indicating that SIRT1 may inhibit the activation of neurons in the VTA and then inhibit the activation of neurons in the NAc, which is a key projectional region of VTA DA neurons.
Figure 3: Effects of SRT1720 on pain behavior and VTA neuronal activation in CCI mice. CCI mice exhibited thermal hyperalgesia in the affected hind paws, which was relieved by SRT1720 (a). The expression of SIRT1 in the contralateral VTA was inhibited by CCI but upregulated by SRT1720 (b). The increased level of acetyl-histone 3 in the contralateral VTA induced by CCI was downregulated by SRT1720 (c). The increased expression of Fos in the contralateral VTA neurons induced by CCI was inhibited by SRT1720 (d). Data are presented as mean ± SD. n = 6 mice per group (n = 3 in the coimmunoprecipitation experiment). *P < 0.05, ** P < 0.01 versus the sham-operated group, # P < 0.05, and ## P < 0.01 versus the CCI group.
Figure 4: Effects of EX-527 on pain behavior and VTA neuronal activation in CCI mice. EX-527 significantly reduced the TWL in sham-operated mice and further reduced the TWL in CCI mice (a). The expression of SIRT1 in the contralateral VTA of sham-operated and CCI mice was inhibited by EX-527 (b). The level of acetyl-histone 3 in the contralateral VTA of sham-operated and CCI mice was increased by EX-527 (c). The expression of Fos in the contralateral VTA of sham-operated and CCI mice was upregulated by EX-527 (d). Data are presented as mean ± SD. *n = 6 mice per group (n = 3 in the coimmunoprecipitation experiment). *P < 0.05, **P < 0.01 versus the sham-operated group, #P < 0.05, and ##P < 0.01 versus the CCI group.
5. Conclusions

Taken together, the present study manifests that the decrease in SIRT1 in the VTA may contribute to the neuropathic pain and the activation of neurons in the VTA and NAc in CCI mice. Upregulation of SIRT1 in the VTA can alleviate neuropathic pain and inhibit the activation of neurons in the VTA and NAc induced by CCI. Our findings may provide a novel insight for the analgesic effect of the VTA-NAc pathway and provide useful information for developing new strategies to treat neuropathic pain.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This study was supported by the Foundation Research Project of Huai’an (HAB2017029).

References

[1] T. Knight, C. Schaefer, A. Chandran, G. Zlateva, A. Winkelmann, and S. Perrot, “Health-resource use and costs associated with fibromyalgia in France, Germany, and the United States,” *ClinicoEconomics and Outcomes Research*, vol. 5, pp. 171–180, 2013.

[2] B. Gannon, D. P. Finn, D. O’Gorman, N. Ruane, and B. E. McGuire, “The cost of chronic pain: an analysis of a regional pain management service in Ireland,” *Pain Medicine*, vol. 14, no. 10, pp. 1518–1528, 2013.

[3] K. Waddell, K. A. Moat, and J. N. Lavis, *Evidence Brief: Developing a National Pain Strategy for Canada*, McMaster Health Forum, Hamilton, Canada, 2017.

[4] M. L. Baldwin, “Reducing the costs of work-related musculoskeletal disorders: targeting strategies to chronic disability cases,” *Journal of Electromyography and Kinesiology*, vol. 14, no. 1, pp. 33–41, 2004.

[5] A. Berger, E. M. Dukes, and G. Oster, “Clinical characteristics and economic costs of patients with painful neuropathic disorders,” *The Journal of Pain*, vol. 5, no. 3, pp. 143–149, 2004.

[6] R.-D. Treede, T. S. Jensen, J. N. Campbell et al., “Neuropathic pain: redefinition and a grading system for clinical and research purposes,” *Neurology*, vol. 70, no. 18, pp. 1630–1635, 2008.

[7] N. Torrance, B. H. Smith, M. I. Bennett, and A. J. Lee, “The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey,” *The Journal of Pain*, vol. 7, no. 4, pp. 281–289, 2006.

[8] D. Bouhassira, M. Lantéri-Minet, N. Attal, B. Laurent, and C. Touboul, “Prevalence of chronic pain with neuropathic characteristics in the general population,” *Pain*, vol. 136, no. 3, pp. 380–387, 2008.

[9] D. Bouhassira, “Neuropathic pain: definition, assessment and epidemiology,” *Revue Neurologique*, vol. 175, no. 1-2, pp. 16–25, 2019.

[10] C. J. Woolf, “Central sensitization: implications for the diagnosis and treatment of pain,” *Pain*, vol. 152, no. 3, pp. S2–S15, 2011.
[11] Y.-Y. Yan, C.-Y. Li, L. Zhou, L.-Y. Ao, W.-R. Fang, and Y.-M. Li, "Research progress of mechanisms and drug therapy for neuropathic pain," *Life Sciences*, vol. 190, pp. 68–77, 2017.

[12] A. Latremoliere and C. J. Woolf, "Central sensitization: a generator of pain hypersensitivity by central neural plasticity," *The Journal of Pain*, vol. 10, no. 9, pp. 895–926, 2009.

[13] X. Yang, G. He, X. Zhang et al., "Transient inhibition of LIMKs significantly attenuated central sensitization and delayed the development of chronic pain," *Neuropharmacology*, vol. 125, pp. 284–294, 2017.

[14] M. A. Ungless, P. J. Magill, and J. P. Bolam, "Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli," *Science*, vol. 303, no. 5666, pp. 2040–2042, 2004.

[15] P. B. Wood, "Mesolimbic dopaminergic mechanisms and pain control," *Pain*, vol. 120, no. 3, pp. 230–234, 2006.

[16] F. Brischoux, S. Chakraborty, D. I. Briereley, and M. A. Ungless, "Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli," *Proceedings of the National Academy of Sciences*, vol. 106, no. 12, pp. 4894–4899, 2009.

[17] R. W. Gear and J. D. Levine, "Nucleus accumbens facilitates nociception," *Experimental Neurology*, vol. 229, no. 2, pp. 502–506, 2011.

[18] M. L. Loggia, C. Berna, J. Kim et al., "Disrupted brain circuitry for pain-related reward/punishment in fibromyalgia," *Arthritis & Rheumatology*, vol. 66, no. 1, pp. 203–212, 2014.

[19] M. N. Baliki and A. V. Apkarian, "Nociception, pain, negative moods, and behavior selection," *Neuron*, vol. 87, no. 3, pp. 474–491, 2015.

[20] N. Schwartz, P. Temkin, S. Jurado et al., "Decreased motivation during chronic pain requires long-term depression in the nucleus accumbens," *Science*, vol. 345, no. 6196, pp. 535–542, 2014.

[21] C.-W. Woo, M. Roy, J. T. Buhle, and T. D. Wagner, "Distinct brain systems mediate the effects of nociceptive input and self-regulation on pain," *PloS Biology*, vol. 13, no. 1, Article ID e1002036, 2015.

[22] H. Zhang, Y.-L. Qian, C. Li et al., "Brain-derived neutrotrophic factor in the mesolimbic reward circuitry mediates nociception in chronic neuropathic pain," *Biological Psychiatry*, vol. 82, no. 8, pp. 608–618, 2017.

[23] L. Becerra, H. C. Breiter, R. Wise, R. G. Gonzalez, and A. Borsook, "Reward circuitry activation by noxious thermal stimuli," *Neuron*, vol. 32, no. 5, pp. 927–946, 2001.

[24] M. N. Baliki, P. Y. Gheh, H. L. Fields, and A. V. Apkarian, "Predicting value of pain and analgesia: nucleus accumbens response to noxious stimuli changes in the presence of chronic pain," *Neuron*, vol. 66, no. 1, pp. 149–160, 2010.

[25] R. Takeda, T. Ikeda, F. Tsuda et al., "Unilateral lesions of mesostriatal dopaminergic pathway alters the withdrawal response of the rat hindpaw to mechanical stimulation," *Neuroscience Research*, vol. 52, no. 1, pp. 31–36, 2005.

[26] M. Moradi, M. Yazdaniian, and A. Haghpurast, "Role of dopamine D2-like receptors within the ventral tegmental area and nucleus accumbens in antinoceptive induction caused by lateral hypothalamic stimulation," *Behavioural Brain Research*, vol. 292, pp. 508–514, 2015.

[27] M. Watanabe, M. Narita, Y. Hamada et al., "Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer," *Molecular Pain*, vol. 14, Article ID 1744806918756406, 2018.

[28] R. Sarkis, N. Saadé, S. Atweh, S. Jabbur, and H. Al-Amin, "Chronic dicyclonine or apomorphine and development of neuropathy in two rat models I: behavioral effects and role of nucleus accumbens," *Experimental Neurology*, vol. 228, no. 1, pp. 19–29, 2011.

[29] P.-C. Chang, S. L. Pollema-Mays, M. V. Centeno et al., "Role of nucleus accumbens in neuropathic pain: linked multi-scale evidence in the rat transitioning to neuropathic pain," *Pain*, vol. 155, no. 6, pp. 1128–1139, 2014.

[30] S. L. Pollema-Mays, M. V. Centeno, Z. Chang, A. V. Apkarian, and M. Martina, "Reduced Aβ-4 expression in the rat nucleus accumbens has causal role in the neuropathic pain phenotype," *Neuroscience Letters*, vol. 702, pp. 77–83, 2019.

[31] M. C. Haigis and D. A. Sinclair, "Mammalian sirtuins: biological insights and disease relevance," *Annual Review of Pathology: Mechanisms of Disease*, vol. 5, no. 1, pp. 253–295, 2010.

[32] L. Guarente, "Sirtuins, aging, and medicine," *New England Journal of Medicine*, vol. 364, no. 23, pp. 2235–2244, 2011.

[33] A. Chalkiadaki and L. Guarente, "Sirtuins mediate mammalian metabolic responses to nutrient availability," *Nature Reviews Endocrinology*, vol. 8, no. 5, pp. 287–296, 2012.

[34] R. H. Houtkooper, E. Pirinen, and J. Auwerx, "Sirtuins as regulators of metabolism and healthspan," *Nature Reviews Molecular Cell Biology*, vol. 13, no. 4, pp. 225–238, 2012.

[35] A. Kauppinen, H. Niskanen, T. Suuronen, K. Kinnunen, A. Salminen, and K. Kaarniranta, "Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells-implications for age-related macular degeneration (AMD)," *Immunology Letters*, vol. 147, no. 1-2, pp. 29–33, 2012.

[36] D. Ferguson, J. W. Koo, J. Feng et al., "Essential role of SIRT1 signaling in the nucleus accumbens in cocaine and morphine action," *Journal of Neuroscience*, vol. 33, no. 41, pp. 16088–16098, 2013.

[37] D. Ferguson, N. Shao, E. Heller et al., "SIRT1-FOXO3a regulate cocaine actions in the nucleus accumbens," *Journal of Neuroscience*, vol. 35, no. 7, pp. 3100–3111, 2015.

[38] H.-D. Kim, J. Hesterman, T. Cali et al., "SIRT1 mediates depression-like behaviors in the nucleus accumbens," *Journal of Neuroscience*, vol. 36, no. 32, pp. 8441–8452, 2016.

[39] S. Libert, K. Pointer, E. L. Bell et al., "SIRT1 activates MAO-A in the brain to mediate anxiety and exploratory drive," *Cell*, vol. 147, no. 7, pp. 1459–1472, 2011.

[40] W. Renthal, A. Kumar, G. Xiao et al., "Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtuins," *Neuron*, vol. 62, no. 3, pp. 335–348, 2009.

[41] R. W. Logan, P. K. Parekh, G. N. Kaplan et al., "NAD+ cellular redox and SIRT1 regulate the diurnal rhythms of tyrosine hydroxylase and conditioned cocaine reward," *Molecular Psychiatry*, vol. 24, no. 11, pp. 1668–1684, 2019.

[42] J. Kong, C. Du, L. Jiang et al., "Nicotinamide phosphoribosyltransferase regulates cocaine reward through Sirtuin 1," *Experimental Neurology*, vol. 307, pp. 52–61, 2018.

[43] Z. Zhang, X. Ding, Z. Zhou et al., "Sirtuin 1 alleviates diabetic neuropathic pain by regulating synaptic plasticity of spinal dorsal horn neurons," *Pain*, vol. 160, no. 5, pp. 1082–1092, 2019.

[44] C.-H. Zhou, M.-X. Zhang, S.-S. Zhou et al., "SIRT1 attenuates neuropathic pain by epigenetic regulation of mGluR1/5 expressions in type 2 diabetic rats," *Pain*, vol. 158, no. 1, pp. 130–139, 2016.

[45] S. Chen, Y. Gu, Q. Dai, Y. He, and J. Wang, "Spinal miR-34a regulates inflammatory pain by targeting SIRT1 in complete Freund’s adjuvant mice," *Biochemical and Biophysical Research Communications*, vol. 516, no. 4, pp. 1196–1203, 2019.

[46] X. L. Yi, S. Yang, L. Wang et al., "Resveratrol inhibits paclitaxel-induced neuropathic pain by the activation of PI3K/akt and..."
siR1/Pgc1α pathway,” Journal of Pain Research, vol. 12, pp. 879–890, 2019.

[47] K. Chen, J. Fan, Z.-F. Luo, Y. Yang, W.-J. Xin, and C.-C. Liu, “Reduction of SIRT1 epigenetically upregulates NALP1 expression and contributes to neuropathic pain induced by chemotherapeutic drug bortezomib,” Journal of Neuroinflammation, vol. 15, no. 1, pp. 1–10, 2018.

[48] J. Zhang, C. Lv, H.-n. Wang, and Y. Cao, “Synergistic interaction between total glucosides and total flavonoids on chronic constriction injury induced neuropathic pain in rats,” Journal of Neuroinflammation, vol. 15, no. 1, pp. 1–10, 2018.

[49] J. Zhang, C. Lv, H.-n. Wang, and Y. Cao, “Synergistic interaction between total glucosides and total flavonoids on chronic constriction injury induced neuropathic pain in rats,” Pharmaceutical Biology, vol. 51, no. 4, pp. 455–462, 2013.

[50] J. Zhang, C. Lv, H.-n. Wang, and Y. Cao, “Synergistic interaction between total glucosides and total flavonoids on chronic constriction injury induced neuropathic pain in rats,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 5, pp. 7152–7161, 2015.

[51] W. Hou, B. Shyu, T. Chen, J. Lee, J. Shieh, and W. Sun, “Intrathecally administered c-fos antisense oligodeoxynucleotide decreases formalin-induced nociceptive behavior in adult rats,” European Journal of Pharmacology, vol. 329, no. 1, pp. 17–26, 1997.

[52] J. Bennett and Y.-K. Xie, “A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man,” Pain, vol. 33, no. 1, pp. 87–107, 1988.

[53] K. Hargreaves, R. Dubner, F. Brown, C. Flores, and J. Joris, “A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia,” Pain, vol. 32, no. 1, pp. 77–88, 1988.

[54] Q. Yin, F.-F. Lu, Y. Zhao et al., “Resveratrol facilitates pain attenuation in a rat model of neuropathic pain through the activation of spinal Sirt1,” Regional Anesthesia and Pain Medicine, vol. 38, no. 2, pp. 93–102, 2013.

[55] Y. Dai, T. Moriymama, T. Higashi et al., “Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain,” Journal of Neuroscience, vol. 24, no. 18, pp. 4293–4299, 2004.

[56] K. M. Ogilvie, S. Lee, and C. Rivier, “Divergence in the expression of molecular markers of neuronal activation in the parvocellular paraventricular nucleus of the hypothalamus evoked by alcohol administration via different routes,” Journal of Neuroscience, vol. 18, no. 11, pp. 4344–4352, 1998.

[57] K. Ren, E. Blass, and R. Dubner, “Suckling and sucrose ingestion suppress persistent hyperalgesia and spinal Fos expression after forepaw inflammation in infant rats,” Proceedings of the National Academy of Sciences, vol. 94, no. 4, pp. 1471–1475, 1997.